BioTakeTokenize the research that never got its shot.
RWA put real-world assets on-chain. BioTake pioneers RWIP — real-world intellectual property. Every paper gets an AI Proof-of-Value price, a hard-capped compliant sale, and graduates into a freely tradable token with a real cash floor and real dividends.
The best science dies in the valley of death.
Between a promising paper and a patient’s bedside lies a decade-long funding gap that kills almost everything. Not because the science is wrong — because the capital, and the ability to own its upside, simply doesn’t exist.
of biomedical papers ever reach a human clinical trial
average time from bench to bedside — if it happens at all
typical cost to bring a single therapy to market
of that upside is ownable by the public today
Of everything published, almost nothing survives to a patient — and none of the upside is public.
RWIP re-prices that lost 99% — and lets anyone own the upside before it’s gone.
A new asset class: RWIP
Real-World Intellectual Property. The peer-reviewed medical research that is clinically promising yet never funded to translation — AI-priced, tokenized, and made ownable, tradable and accountable.
RWA tokenizes what you own.
RWIP tokenizes what you know.
Five beliefs that make BioTake inevitable.
RWIP isn’t a feature — it’s a worldview. Here’s the conviction the whole protocol is built on.
Science is the most underpriced asset on Earth
A single paper can seed a billion-dollar therapy — yet ~99% never get the capital to find out. RWIP puts an honest price on that latent potential.
Knowledge should be ownable
RWA made buildings and bonds liquid. Intellectual property — the blueprint of every cure — deserves to be just as ownable, tradable, and composable.
Merit over gatekeepers
A handful of grant panels and funds decide which science lives. An objective AI Proof-of-Value opens that gate to anyone, anywhere.
Alignment by design
Scientists, backers and patients win together: capital unlocks only against real clinical milestones, and revenue returns on-chain as dividends.
Accountability is public
Every valuation, milestone and dollar lives on-chain. No black boxes, no quiet write-offs. Science — but fully auditable.
Paper to funded venture, in five steps.
A single pipeline turns a neglected manuscript into a priced, compliant, milestone-gated on-chain venture — with liquidity and dividends at the end.
Connect your paper
Upload a PDF or import a DOI. The AI extracts the title, abstract, authors and field automatically — no manual forms.
AI Proof-of-Value
Six weighted dimensions produce a composite score and a defensible valuation. The conservative end becomes an on-chain raise cap you can never exceed.
RWIP public sale
KYC'd backers subscribe to a compliant, restricted RWIP security. 10% platform fee on close; the rest splits into a redemption reserve and milestone escrow.
Milestone-gated build
Funds release only against public clinical milestones with budgets, deliverables and deadlines. Everyone watches the roadmap execute on-chain.
Graduate & earn
The sale graduates into a freely tradable Mirror token with a NAV ratchet floor, a 1.5% trade fee, and pro-rata stablecoin dividends from real revenue.
Proof-of-Value: an objective price for science.
Every paper is scored across six weighted dimensions into a composite Proof-of-Value and a valuation range. The conservative end becomes a hard on-chain cap — a founder can never raise above what the research can defend.
The conservative low end is the only number founders can raise against — hype cannot inflate it.
A weighted blend of six dimensions. Anything above ~70 clears our review bar for a compliant public raise.
Safety isn’t a promise. It’s in the contracts.
Every guardrail below is enforced by the protocol itself — not a policy, not a pinky-swear. Code you can read, on a chain you can audit.
AI-hard-capped raise
Founders can never price above the conservative end of the AI valuation. No hype-driven rounds.
NAV ratchet floor
A hard cash-floor per token, backed by the redemption reserve, that only ever rises — real downside protection.
Milestone escrow
Working capital is locked and released only against approved, public clinical deliverables.
KYC & compliance
Restricted security tokens with on-chain allowlisting — built for real-world regulatory reality.
Real dividends
Magnified-dividend distribution streams clinical & licensing revenue back to holders, pro-rata, on-chain.
Dual-layer mirror
An SPV equity vault anchors the on-chain token, bridging a compliant RWIP security to a liquid asset.
One protocol. Three winners.
RWIP aligns the people who have historically been forced to compete for the same scarce grant dollars.
For scientists
Fund the work, keep the equity- Turn a paper into funding — no grant panels, no gatekeepers
- Keep your equity; raise against milestones, not deadlines
- A public roadmap that builds your credibility on-chain
For backers
Own the upside, priced by AI- Own upside in breakthrough research, priced by AI
- NAV floor downside protection + real stablecoin dividends
- Liquid from day one — trade RWIP, don't lock it away
For patients & science
Accelerate the cures- Accelerate the cures stuck in the valley of death
- Fully transparent: every dollar and milestone is auditable
- Merit-based funding that reaches underrepresented research
Questions, answered.
01What exactly is RWIP?+
RWIP — Real-World Intellectual Property — is a new on-chain asset class. Where RWA tokenizes physical and financial assets (real estate, treasuries), RWIP tokenizes intellectual property: peer-reviewed papers, patents, clinical data and their translation rights, starting with medical research.
02How does the AI price a paper?+
The Proof-of-Value engine scores each paper across six weighted dimensions — scientific feasibility, clinical utility, commercial value, competitive landscape, IP strength and team — into a composite score and a valuation range. The conservative (low) end becomes the on-chain raise cap; founders can never price above it.
03What backs the token's value?+
Two things: a NAV ratchet floor — a hard, only-rising cash floor per token backed by the redemption reserve — and the project's milestone-escrowed working capital plus any clinical/licensing revenue that later flows in as dividends.
04What do I actually own?+
During the sale you hold a compliant, restricted RWIP security (BioShares) backed by SPV equity. At graduation it mirrors into a freely tradable Mirror token that carries the NAV floor, dividend rights and secondary liquidity.
05What happens if a project fails to raise or deliver?+
If a sale doesn't hit its minimum, subscriptions are refunded. Post-sale, working capital is milestone-escrowed and only releases against approved deliverables — and holders can always redeem at the NAV floor.
06Is this a security? Do I need KYC?+
Yes — RWIP tokens are treated as security-type instruments. Wallets are KYC-allowlisted on-chain before they can subscribe or hold, by design. This is a testnet demo and not investment advice.
Own the research that changes medicine.
Back a breakthrough, or bring your own paper on-chain. RWIP starts here.